Michael Yeadon

Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom.

Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA.

Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO.

Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO.

Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom.